Article Text

other Versions

PDF
Nestin is expressed in basal-like and triple negative breast cancers
  1. Suzanne Parry (suzanne.parry{at}icr.ac.uk)
  1. Institute of Cancer Research, United Kingdom
    1. Kay Savage (kay.savage{at}icr.ac.uk)
    1. Institute of Cancer Research, United Kingdom
      1. Caterina Marchio (caterina.marchio{at}icr.ac.uk)
      1. Institute of Cancer Research, United Kingdom
        1. Jorge Sergio Reis Filho (jorgerf{at}icr.ac.uk)
        1. Institute of Cancer Research, United Kingdom

          Abstract

          Aims: To analyse the distribution of Nestin expression in different breast tumours and to determine the prognostic impact of Nestin expression.

          Methods: Nestin expression was immunohistochemically analysed in a cohort of 245 invasive breast cancer patients treated with therapeutic surgery followed by anthracycline-based chemotherapy using a semi-quantitative scoring system.

          Results: Nestin was exclusively expressed in grade III breast carcinoma and preferentially expressed in basal-like and triple negative cancers. Nestin-positive tumours displayed high proliferation rates and p53 nuclear expression. Lymph-node positive patients with Nestin-positive cancers had a shorter breast cancer specific survival; however Nestin was not an independent prognostic factor on multivariate analysis.

          Conclusions: Nestin expression is preferentially found in basal-like and triple negative breast carcinomas. Further studies are warranted to define the biological role played by Nestin in these subgroups of breast cancers.

          Statistics from Altmetric.com

          Request permissions

          If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.